Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.
about
The epithelial cell adhesion molecule EpCAM is required for epithelial morphogenesis and integrity during zebrafish epiboly and skin developmentIdentification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytesEpCAM (CD326) finding its role in cancerThe epithelial cellular adhesion molecule (Ep-CAM) is a ligand for the leukocyte-associated immunoglobulin-like receptor (LAIR)Biological response modifiers in cancerThe significance of tumor-associated immune response in molecular taxonomy, prognosis and therapy of colorectal cancer patientsInsight to drug delivery aspects for colorectal cancerProduction of monoclonal antibodies in plants for cancer immunotherapyInfluence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expressionA3--a novel colon and pancreatic cancer reactive antibody from a primate phage library selected using intact tumour cells.Initial activation of EpCAM cleavage via cell-to-cell contact.Determination of disulfide bond assignments and N-glycosylation sites of the human gastrointestinal carcinoma antigen GA733-2 (CO17-1A, EGP, KS1-4, KSA, and Ep-CAM).A human immunoglobulin G1 antibody originating from an in vitro-selected Fab phage antibody binds avidly to tumor-associated MUC1 and is efficiently internalized.Detection and clinical importance of micrometastatic disease.Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives.Nuclear and cytoplasmic accumulation of Ep-ICD is frequently detected in human epithelial cancers.Inhibition of tumor growth by plant-derived mAb.An overview of cancer immunotherapy.Minimal residual marrow disease: detection and significance of isolated tumour cells in bone marrow.High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibodyExpression pattern of epithelial cell adhesion molecule on normal and malignant colon tissuesHeterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells.Implications of occult metastatic cells for systemic cancer treatment in patients with breast or gastrointestinal cancer.Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments.Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review.Growth suppression of colorectal cancer by plant-derived multiple mAb CO17-1A × BR55 via inhibition of ERK1/2 phosphorylation.Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas.Nuclear Ep-ICD expression is a predictor of poor prognosis in "low risk" prostate adenocarcinomasAdjuvant therapy for colon cancer in the new millenium.Construction, expression, and characterization of a recombinant immunotoxin targeting EpCAM.The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathologyVariation in gene expression patterns in human gastric cancers.Molecular biological design of novel antineoplastic therapies.The role of chemotherapy in colon cancer.The tissue micro-array as a translational research tool for biomarker profiling and validation.Exploring Different Strategies for Efficient Delivery of Colorectal Cancer TherapyAn anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer.Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer.Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen.Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival.
P2860
Q21563339-5D5C7D6A-E462-48EB-8109-4844F68F6C2BQ24649346-37F74418-3ECD-4C03-BDAB-D8FA4CAED5E8Q24653692-938E51F2-D6C2-4B60-8A4B-DC1A5D0FE90CQ24675606-F22BE59C-071E-48C6-B681-BE46CC446D6CQ24685049-772498B8-A9DE-4465-9C05-B8030E23624BQ26738665-E091DB2C-2BC7-4847-988B-F6553392E66CQ26774682-3CA078ED-DA58-4B23-AB7A-EBBA8A399BB1Q26778423-9B257884-842C-40F7-ACE3-9305841F6576Q28347115-AF8DB120-5194-43FF-9317-67F0C23A0898Q30890906-3DC1EF01-317A-4E13-938B-83CB9920C7F3Q30898801-473E7346-E403-41AB-87AE-D18BACDD5F41Q30963142-E43E3933-1662-4361-91EA-35C035665ECEQ31051574-08EB8621-ABEC-43E2-99EC-65579A11E210Q33678970-089CE543-3E91-4FA9-8914-9150C99ADB2CQ33755476-0A52755C-F703-41BF-9397-CFC17401ECF3Q33770286-CC8B36FF-D54E-43B7-B07C-FD8C4403CEBBQ33784553-8ABD3FAB-2DCF-48B0-9078-EAC53465C1E7Q33940388-0E14D8E8-24B7-4416-BEC9-03BFDA12313AQ34284347-EF135DDC-31EA-4FA7-8420-0DF61D492ABAQ34361383-ED845EB0-0288-4691-89D8-BDA235383A10Q34382238-1652C4E7-5E18-4C6C-9D6A-456CAA17F608Q34404833-769BDBFB-81E0-4CDE-9D8B-7C91D344A5AEQ34465224-D97C87AF-F1C5-459E-9CA6-891D2D96D675Q34478304-E3145A49-973A-4649-A864-0D282B6DE582Q34585684-A6432578-DA46-420D-9040-B369B2A612ABQ34685644-AB4095B8-2748-4D5F-B73E-DBDCE60ECAE9Q34912810-368F25F9-0E2B-47F0-9AA0-8E2E2CA93C2AQ35103343-AB5E4DF6-B8F7-48A3-9184-5D9CF3EF26C9Q35111174-536A9224-ACDE-4B38-85C7-C33513DFC021Q35556641-A5D276B1-0741-43C7-A159-5AE4F9B833FDQ35591389-42B7C452-68FB-4D3B-959A-A57DFB32FEA9Q35670324-6FE67419-BD87-436A-8D63-FC1C9D23078EQ35790781-2B432427-6154-4E30-876E-264FCDDBB81EQ36101808-58DDA93E-4D0A-4A02-BB4B-D34CBDDF8EFDQ36318018-39D49753-1DD8-4893-935D-F633CF25DF51Q36324618-CBE2F83F-284E-4669-9A95-F5EC27982930Q36413078-202F97F1-64CC-4492-A480-110B97748630Q36621482-041154E8-1688-40A6-9972-99F32C54F500Q36623092-F99D7CCC-0B55-487B-8C6C-D768236D9B16Q36649103-2A99D426-D064-41AF-BEAD-B12F9FA74CD7
P2860
Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Monoclonal antibody therapy fo ...... multicenter randomized trial.
@en
Monoclonal antibody therapy fo ...... multicenter randomized trial.
@nl
type
label
Monoclonal antibody therapy fo ...... multicenter randomized trial.
@en
Monoclonal antibody therapy fo ...... multicenter randomized trial.
@nl
prefLabel
Monoclonal antibody therapy fo ...... multicenter randomized trial.
@en
Monoclonal antibody therapy fo ...... multicenter randomized trial.
@nl
P2093
P1476
Monoclonal antibody therapy fo ...... multicenter randomized trial.
@en
P2093
G Riethmüller
G Schlimok
H Pichlmaier
P Buggisch
P304
P356
10.1200/JCO.1998.16.5.1788
P407
P577
1998-05-01T00:00:00Z